Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 (CYP) 3A, inhibit CYP2C9, CYP2C19 and P‐glycoprotein (P‐gp). Herein, 2 open‐label, single‐sequence, crossover stud...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Autores principales: Zahir, Hamim, Kobayashi, Fumiaki, Zamora, Cynthia, Gajee, Roohi, Gordon, Michael S., Babiker, Hani M., Wang, Qiang, Greenberg, Jonathan, Wagner, Andrew J.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Drug Interactions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7891582/
https://ncbi.nlm.nih.gov/pubmed/32918831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1734
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares